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Another propensity score analysis compared SBRT with 
sublobar resection for stage I NSCLC in patients at high risk 
for lobectomy (8). In 53 matched pairs the difference in 
overall survival was not significant and the cumulative 
incidence of cause-specific death was comparable between 
both groups. Conclusion of this study was that SBRT can be an 
alternative treatment option to sublobar resection for 
patients with severe comorbidity who cannot tolerate 
alobectomy due to functional impairment (8).  
In June 2015 the “Comité del’Evolution des Pratiques en 
Oncologie (CEPO) from Québec, Canada published 
recommendations regarding the use of SBRT (9). For 
medically operable patients with T1-2N0M0 NSCLC surgery 
remains the standard treatment due to the lack of high-level 
evidence and valid comparative data. For medically 
inoperable patients withT1-2N0M0 NSCLC or medically 
operable patients who refuse surgery, SBRT should be 
preferred to external beam radiotherapy. In the latter cases 
a biological equivalent dose (BED) of at least 100 Gy should 
be administered. The choice ofusing SBRT should be 
discussed within a multidisciplinary tumor board. 
Radiotherapy should not be considered for patients whose life 
expectancy is very limited because of comorbidities.  
In summary, main points are: 
· surgical resection remains the treatment of choice for 
operable early-stage NSCLC  
· SBRT may be considered for functionally compromised 
patients who cannot tolerate lobectomy.  
· further high-level evidence is needed which requires close 
cooperation between radiation oncologists and thoracic 
surgeons to design comparative trials with clear inclusion 
criteria and unequivocal definitions of endpoints.  
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Debate: Is brachytherapy the best for partial breast 
irradiation?  
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Accelerated Partial Breast Irradiation (APBI) using 
multicatheter brachytherapy is an attractive treatment 
approach not only to shorten the course of radiation therapy 
from 3-6 weeks to 2-5 days but also to reduce significantly 
the radiation exposure to the breasts, the skin, the lung and 
particularly to the heart very effectively.  
Over the last 20 years different modalities of APBI have been 
introduced into clinical practice –multicatheter 
brachytherapy, single catheter brachytherapy, IORT 
techniques, different techniques of External Beam Radiation 
Therapy (EBRT). Unfortunately fact is that the results of APBI 
trials with IORT using intraoperative electrons or 50 kV 
photons have been negative. As well Vaidya et al. (TARGIT 
trial) as Veronesi et al. (ELIOT trial) reported high 5-year 
recurrence rate after IORT, namely 3.3%-4.4% in IORT groups 
versus statistically significant lower recurrence rates in 
control groups 0.4%-1.3%. Possibility of APBI using EBRT is of 
course very attractive, since this technique is broadly 
available and easy to perform. Unfortunately, hitherto 
reported results of phase 3 APBI trials using EBRT are either 
disappointing (RAPID trial) or with low statistical power 
(Olivotto et al., Livi et al.). On the contrary, during the last 
decade number of modern phase 2 and phase 3 APBI trials, 
using multicatheter interstitial brachytherapy for the delivery 
of APBI, have demonstrated favorable long-term local control 
rates and cosmetic outcomes, comparable to the results of 
whole breast irradiation (WBI). In the largest phase 3 
randomized non-inferiority GEC-ESTRO trial with sufficient 
statistical power (~1200 pts.), importantly using for APBI 
solely multicatheter interstitial brachytherapy in 5 days, 
after median follow-up of 6.6 years the 5-year local 
recurrence rates were 1.4% in the APBI arm, and 0.9% in the 
WBI arm (p=0.4), and 5-year disease-free and overall survival 
were 96-97% in the WBI group versus 97% in the APBI group - 
all events are without any statistical and clinical significance. 
The equivalence of local recurrence rates was evident in all 
age groups, in all histological subgroups and also independent 
of the type of systemic therapy. Thus it´s the first phase 3 
study proving non-inferiority of APBI in comparison to whole 
breast irradiation for selected early stage breast cancer 
patients. Undoubted is, that in the light of the landmark UK 
and Canadian trials comparing 5 versus 3 weeks of WBI the 
difference in total treatment time between WBI and APBI 
using multicatheter brachytherapy (4-5 days) has been 
partially diminished. However the difference between 3 
weeks of WBI versus 4-5 days of APBI still remains clinically 
and socio-economically relevant. Moreover, due to the 
extreme steep fall-off of dose of Iridum-192, the significant 
dose reduction of irradiated normal tissues (including the 
heart and skin) is a unique advantage of interstitial 
multicatheter brachytherapy, which is hardly ever achievable 
by other APBI techniques. The remaining, hitherto 
unreported ongoing APBI trials unfortunately use for APBI 
only different techniques of EBRT. The results of these trials 
will therefore particularly contribute to further fine-tuning of 
selection criteria and to precise requirements for quality 
assurance of EBRT-based APBI.  
In summary: At the present time only the long-term results of 
APBI using sole multicatheter brachytherapy for appropriate 
selected patients demonstrate impressive low local 
recurrence rates – similar as WBI, accompanying with 
excellent radiation protection of surrounding organs – better 
as WBI. Consequently “APBI used multicatheter 
brachytherapy is today a proven and valid alternative 
treatment option after breast conserving surgery, and can be 
offered for all low risk breast cancer patients in clinical 
routine”. 
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Over the past ten years the results of several clinical trials 
have been published, detailing various approaches of PBI. 
Among the different techniques used, IORT has increased 
rapidly in popularity, mainly in Europe, and up to date many 
thousands of women have been treated in clinical setting. 
IORT allows to realize a radiation dose to the index quadrant, 
eliminating the treatment to the tissue remote from the 
tumour bed, and using only one very high dose (20 Gy or 
more) in a single session. When single doses above certain 
thresholds of 10 Gy are given, some additional biological 
effects on tumor cell killing and from the surrounding 
microenvironment can be expected. IORT also represents the 
possibility of overcoming some constraints such as the 
accessibility to the centres of radiotherapy, the socio-
economic impact on the working life and on the personal 
habits of the patient. Another important advantage is the 
avoidance of the interactions with the systemic therapy, that 
may determine delays in the initiation or in the carrying out 
of the adjuvant treatment. These potential benefits must be 
balanced with the potential higher risk of recurrence within 
the untreated gland tissue in the same breast as well as the 
still unknown long-term results on survival and cosmesis. Two 
prospective randomized clinical studies establishing the role 
of IORT in clinical practice have been published up to now. A 
single-center study, named ELIOT, was performed at the 
European Institute for Oncology (EIO) in Milan, Italy. Patients 
with limited size tumor (2.5 cm) and age of 48 years or more 
were either randomized to a single dose of 21 Gy of IORT 
with electrons or to standard WBI. The local recurrence rate 
(LRR) at 5-years was higher in the experimental arm (4.4% 
